Titel

Merkliste
1 Ergebnisse

PFS, OS, ORR, and DCR of Re-Cx for 30 cases:

Masashi Ishikawa (738977) ; Atsuo Takashima (10268537) ; Yusuke Nagata (7457706)...
https://figshare.com/articles/figure/PFS_OS_ORR_and_DCR_of_Re-Cx_for_30_cases_/16678314. , 2021

Link: https://doi.org/10.1371/journal.pone.0257551.g001

RT Journal
T1 <Title>PFS, OS, ORR, and DCR of Re-Cx for 30 cases</Title>

UL https://suche.suub.uni-bremen.de/peid=base-ftsmithonian:oai:figshare.com:article_16678314&Exemplar=1&LAN=DE
				
A1 Masashi Ishikawa (738977)
A1 Atsuo Takashima (10268537)
A1 Yusuke Nagata (7457706)
A1 Ryoichi Sawada (10336554)
A1 Masahiko Aoki (9520703)
A1 Hiroshi Imazeki (11478300)
A1 Hidekazu Hirano (11478303)
A1 Hirokazu Shoji (6987395)
A1 Yoshitaka Honma (547718)
A1 Satoru Iwasa (3762730)
A1 Natsuko Okita (11478306)
A1 Ken Kato (785312)
A1 Masayuki Saruta (3543728)
A1 Narikazu Boku (10336557)
YR 2021
K1 Genetics
K1 Pharmacology
K1 Biotechnology
K1 Immunology
K1 Cancer
K1 Infectious Diseases
K1 results also suggested
K1 objective response rate
K1 metastatic colorectal cancer
K1 18 cases )
K1 tumor growth rate
K1 disease control rate
K1 retrospective study evaluated
K1 indicates tumor shrinkage
K1 8 cases )
K1 3 cases )
K1 previously used agents
K1 tumor shrinkage
K1 30 cases
K1 12 cases
K1 disease progression
K1 xlink ">
K1 tumor efficacy
K1 salvage treatment
K1 oxaliplatin based
K1 overall survival
K1 october 2018
K1 occasionally reused
K1 november 2011
K1 median progression
K1 measurable lesions
K1 mcrc )
K1 free survival
K1 discontinued due
K1 clinical practice
K1 chemotherapeutic agents
K1 87 %)
K1 57 months
K1 3 %)
K1 25 patients
JF https://figshare.com/articles/figure/PFS_OS_ORR_and_DCR_of_Re-Cx_for_30_cases_/16678314
LK http://dx.doi.org/https://doi.org/10.1371/journal.pone.0257551.g001
DO https://doi.org/10.1371/journal.pone.0257551.g001
SF ELIB - SuUB Bremen

Export

RefWorks (nur Desktop-Version!)
Flow (Zuerst in Flow einloggen, dann importieren)